Table II.
Clinical manifestations depending on the incidence of the type of anti-ARS antibodies (ASA) in the group of 50 analyzed patients
| Type of antibody | n | Muscle weakness n (%) | Body mass loss n (%) | Joint involvement n (%) | Pulmonary involvement n (%) | Skin involvement n (%) | Heart involvement n (%) | Dysphagia n (%) | CK elevation n (%) | CRP elevation n (%) | Fever n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jo-1 | 23 | 11 (47.8) | 2 (8.7) | 15 (65.2) | 11 (47.8) | 14 (60.8) | 2 (8.7) | 1 (4.3) | 10 (43.4) | 10 (43.4) | 6 (26) |
| PL-7 | 8 | 5 (62.5) | 3 (37.5) | 4 (50) | 5 (62.5) | 3 (37.5) | 1 (12.5) | 2 (25) | 3 (37.5) | 2 (25) | 3 (37.5) |
| PL-12 | 16 | 10 (62.5) | 4 (25) | 13 (81.25) | 8 (50) | 5 (31.25) | 1 (6.25) | 4 (25) | 5 (31.25) | 6 (37.5) | 4 (25) |
| OJ | 6 | 4 (66.6) | 2 (33.3) | 3 (50) | 6 (100) | 4 (66.6) | 1 (16.6) | 2 (33.3) | 4 (66.6) | 3 (50) | 3 (50) |
| EJ | 3 | 1 (33.3) | 0 | 3 (100) | 1 (33.3) | 2 (66.6) | 0 | 0 | 0 | 1 (33.3) | 1 (33.3) |
In 6 patients the coexistence of at least one ASA was found. Anti-ARS – anti-aminoacyl tRNA synthetase, ASA – antisynthetase antibodies, CK – creatine kinase, CRP – C-reactive protein, Jo-1 – anti-histidyl tRNA synthetase, PL-7 – anti-threonyl tRNA synthetase, PL-12 – anti-alanyl tRNA synthetase, OJ – anti-isoleucyl tRNA synthetase, EJ – anti-glycyl tRNA synthetase.